A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Study of INBRX 109 in Patients with Metastatic or Inoperable Chondrosarcoma
Sponsor: Inhibrx Inc
Enrolling: Male and Female Patients
IRB Number: AAAT8360
U.S. Govt. ID: NCT04950075
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The experimental drug called INBRX 109 has been developed as a treatment for unresectable or metastatic conventional chondrosarcoma. The purpose of this study is to learn about the effects of the study drug, INBRX-109 on you, your immune system, and your cancer. This study is being done to understand if INBRX-109 is effective against your chondrosarcoma and how safe this drug is. INBRX-109 was specifically created for the treatment of cancer. It works in a similar way as antibodies, which are proteins that are naturally present in the body. Antibodies help the body's immune system fight diseases such as infections. INBRX-109 works by causing specific cell sensors to initiate the death of cancer cells. This is different from the ways other cancer therapies work.
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with chondrosarcoma? Yes No
Is your cancer metastatic or inoperable? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162